NIVOLUMAB and PYREXIA

Overview

PYREXIA is the #6 most commonly reported adverse reaction for NIVOLUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 3,603 FDA adverse event reports linking NIVOLUMAB to PYREXIA. This represents approximately 2.6% of all 139,909 adverse event reports for this drug.

NIVOLUMAB has an overall safety score of 89 out of 100. Patients taking NIVOLUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PYREXIA is a less commonly reported adverse event for NIVOLUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of NIVOLUMAB

In addition to pyrexia, the following adverse reactions have been reported for NIVOLUMAB:

• DEATH — 11,508 reports
• MALIGNANT NEOPLASM PROGRESSION — 9,599 reports
• OFF LABEL USE — 5,881 reports
• DIARRHOEA — 5,008 reports
• FATIGUE — 4,016 reports
• INTENTIONAL PRODUCT USE ISSUE — 3,329 reports
• NAUSEA — 3,054 reports
• RASH — 2,962 reports
• DECREASED APPETITE — 2,792 reports
• DYSPNOEA — 2,623 reports

Other Drugs Associated with PYREXIA

The following drugs have also been linked to pyrexia in FDA adverse event reports:

Does NIVOLUMAB cause PYREXIA?

PYREXIA has been reported as an adverse event in 3,603 FDA reports for NIVOLUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PYREXIA with NIVOLUMAB?

PYREXIA accounts for approximately 2.6% of all adverse event reports for NIVOLUMAB, making it a notable side effect.

What should I do if I experience PYREXIA while taking NIVOLUMAB?

If you experience pyrexia while taking NIVOLUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages